Also trades as: 0R2M.L (LSE) · $vol 1M
REGN NASDAQ
Regeneron Pharmaceuticals, Inc.
1W: -9.8%
1M: -14.0%
3M: -17.6%
YTD: -17.1%
1Y: +4.8%
3Y: -13.0%
5Y: +25.0%
$638.88
-3.71 (-0.58%)
Weekly Expected Move ±4.6%
$634
$666
$698
$730
$763
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.90
Bullish
2 bullish
0 neutral
0 bearish
Articles (24h)
2
Hourly Sentiment (24h)
Articles (1)
0.00
Neutral
8 bullish
1 neutral
8 bearish
Articles (7d)
17
Daily Sentiment (7 Days)
Articles (100)
Here's Why Regeneron (REGN) is a Strong Value Stock
Otarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss
Lynozyfic® (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis
BAYRY's Kerendia Label Expansion Application Gets Priority Review
$100 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth This Much Today
Regeneron & Parabilis Sign Oncology Collaboration Worth Up to $2.2B
Can Intellia's Pipeline Push Drive Long-Term Growth Amid Rivalry?
Company News for May 19, 2026
Regeneron's Late-Stage Melanoma Study Misses Primary Goal
Nasdaq 100 Drops Over 1%, Oil Tops $106 On Iran Impasse: Stock Market Today
UnitedHealth, Regeneron Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session
At a glance: stocks gapping down premarket
Why Is Regeneron Stock Sinking Monday?
Why LiveRamp Shares Are Trading Higher By Over 26%; Here Are 20 Stocks Moving Premarket
Stock Market Today: Dow Jones, S&P 500 Futures Drop Following Drone Strike On UAE Nuclear Plant—Regeneron Pharma, NextNRG, ServiceNow In Focus
Stock futures slip ahead of Nvidia earnings later this week
Regeneron hit with late-stage trial setback for Libtayo combo against Merck’s Keytruda
ANI Pharmaceuticals: Rare Disease Shift and the 2026 Playbook
ANIP Valuation: Does 9.8x Forward P/E Offer Upside?
ANIP Stock: What's Driving Cortrophin Gel's 2026 Surge
Trump 'Most Favored Nation' drug policy risks China R&D takeover
NTLA Q1 Earnings Beat Estimates, Revenues Miss Mark, Pipeline in Focus
Bayer Q1 Earnings Beat Estimates, Crop Science Unit Boosts Sales
Will Eli Lilly Be the First $2 Trillion Healthcare Stock? 3 Catalysts That Could Get It There.
Is This Biotech Stock a Buy After a Groundbreaking Approval?
RARE Q1 Loss Wider Than Expected, Sales Down Y/Y on Seasonal Effect
Healthcare earnings impress with 86% beat rate, yet sector lags: Earnings Scorecard
Is Regeneron a Buy After the FDA Approved its Gene Therapy to Restore Hearing?
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 20 Years
Apple To Rally More Than 19%? Here Are 10 Top Analyst Forecasts For Friday
Regeneron Pharmaceuticals Analysts Cut Their Forecasts Following Q1 Earnings
Why Regeneron (REGN) is a Top Value Stock for the Long-Term
Certuity LLC Reduces Stock Position in Regeneron Pharmaceuticals, Inc. $REGN
Regeneron anticipates an EYLEA HD prefilled syringe decision this quarter while updating 2026 GAAP gross margin to 77%-78%
Regeneron Flags FDA Delays For Eylea HD Prefilled Syringe
Oil Surges 6%, S&P 500 Wobbles Before Fed And Tech Earnings: Stock Market Today
Regeneron Q1 Earnings Top, Sales Up on Dupixent & Eylea HD Strength
Regeneron (REGN) Q1 2026 Earnings Transcript
Regeneron (REGN) Reports Q1 Earnings: What Key Metrics Have to Say
Regeneron drops despite Q1 beat, $3B share buyback program
Regeneron (REGN) Surpasses Q1 Earnings and Revenue Estimates
Earnings Scheduled For April 29, 2026
Regeneron Pharmaceuticals Non-GAAP EPS of $9.47 beats by $0.57, revenue of $3.61B beats by $130M
Regeneron Reports First Quarter 2026 Financial and Operating Results
Regeneron Reports First Quarter 2026 Financial and Operating Results
Amgen to Report Q1 Earnings: Can It Keep the Beat Streak Alive?
Is IBRX Priced for Perfection at Nearly 28x Forward Sales?
Will Higher Dupixent Profits, Eylea HD Sales Drive REGN's Q1 Earnings?
Earnings week ahead: MSFT, AAPL, GOOG, AMZN, META, XOM, CVX, KO, V, SBUX, F, GM, and more
Arizona State Retirement System Decreases Holdings in Regeneron Pharmaceuticals, Inc. $REGN
Regeneron Strikes Deal With Trump Administration To Cut Drug Prices
Gear Up for Regeneron (REGN) Q1 Earnings: Wall Street Estimates for Key Metrics
Biogen Q1 Earnings: Can New Launches Offset Declining MS Franchise?
Regeneron Announces Agreement with U.S. Government to Help Lower Drug Costs for American Patients and Will Provide Innovative New Gene Therapy for Free in the U.S.
SNY & REGN's Dupixent Wins FDA Nod for Pediatric Use in Urticaria
Regeneron wins FDA approval for hearing loss therapy
Regeneron is said to have reached a drug pricing deal with U.S.
FDA Approval Broadens Dupixent Use While Sanofi Posts Earnings Beat
Illumina (ILMN) Reports Next Week: Wall Street Expects Earnings Growth
Sanofi Tops Q1 Earnings Estimates as Dupixent & New Drugs Drive Growth
Sanofi and Regeneron’s Dupixent becomes first biologic for kids under 12 with CSU
Dupixent® (dupilumab) Approved in the U.S. as the First Biologic Medicine for Young Children with Uncontrolled Chronic Spontaneous Urticaria (CSU)
Press Release: Sanofi and Regeneron's Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria
Roche Highlights Gazyva Progress, Reports Data on Enspryng, MS Drug
Roche Highlights Gazyva Progress, Reports Data on Enspryng, MS Drug
Regeneron (REGN) Earnings Expected to Grow: Should You Buy?
Got $2,000? These Biotech Stocks Are Worth Considering for Long-Term Growth
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
Belpointe Asset Management LLC Invests $1.74 Million in Regeneron Pharmaceuticals, Inc. $REGN
ANI Pharmaceuticals' 2026 Catalysts Include Gout Push and New Generics
Is ANIP Stock Undervalued at 10x Forward Earnings and $93 Target?
ANIP's Cortrophin Gel Surge Powers 2026 Growth Outlook
First Horizon Corp Has $905,000 Stake in Regeneron Pharmaceuticals, Inc. $REGN
Regeneron Pharmaceuticals, Inc. $REGN Stock Position Lifted by AE Wealth Management LLC
Asset Management One Co. Ltd. Sells 6,358 Shares of Regeneron Pharmaceuticals, Inc. $REGN
3 Catalysts That Could Send Teva Stock to $40 and Beyond
Lbp Am Sa Sells 12,873 Shares of Regeneron Pharmaceuticals, Inc. $REGN
Assetmark Inc. Sells 9,539 Shares of Regeneron Pharmaceuticals, Inc. $REGN
NTLA Stock Rises 20% in 3 Months: Here's What You Should Know
Could AbbVie Crash Lilly's Weight‑Loss Party?
Regeneron Boosts Cancer Pipeline Through Telix Collaboration
Ocular's Axpaxli Cuts Risk Of Worsening In Late-Stage AMD Study
SNY & REGN's Dupixent Gets EU Approval for Pediatric Use in Urticaria
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Telix Pharma Gains As Regeneron Tie-Up Targets Solid Tumor Programs
Regeneron inks deal with Telix for radiopharmaceutical therapies
Telix and Regeneron Announce Strategic Radiopharma Collaboration
Charter Oak Capital Management LLC Buys Shares of 958 Regeneron Pharmaceuticals, Inc. $REGN
Burney Co. Acquires New Shares in Regeneron Pharmaceuticals, Inc. $REGN
Sanofi, Regeneron’s Dupixent approved in EU for young children with chronic urticaria
Press Release: Sanofi and Regeneron's Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria
Dupixent® (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU)
Altfest L J & Co. Inc. Buys 1,275 Shares of Regeneron Pharmaceuticals, Inc. $REGN
Regeneron Pharmaceuticals, Inc. $REGN Stake Raised by Bar Harbor Wealth Management
REGN or ILMN: Which Is the Better Value Stock Right Now?
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Cache Advisors LLC
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Cache Advisors LLC
Regeneron expects ~$102M in Q1 pre-tax IPR&D charges
Asio Capital LLC Makes New $3.42 Million Investment in Regeneron Pharmaceuticals, Inc. $REGN
From Lungs To Nasal Polyps: Sanofi Finds Success With 2-in-1 Inflammation Blocker